Then, a phase I dose-escalation trial produced vaccines with RNA-lipoplexes encoding melanoma-associated malignant antigens, including New York-ESO 1 (NY-ESO-1), tyrosinase, melanoma-associated antigen A3 (MAGE-A3), and transmembrane phosphatase with tensin homology (TPTE) (NCT02410733) [7]. This evidence concerns the gene TPTE and melanoma.